Patents Examined by Jeanette Lieb
  • Patent number: 9827272
    Abstract: Provided herein are hydrogel cell matrices, hydrogel cell matrix systems for the support, growth, and differentiation of a stem cell or progenitor cell and methods for making such hydrogel cell matrices.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: November 28, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Amit Kumar Jha, Kevin E. Healy
  • Patent number: 9827245
    Abstract: Described herein are compositions of keratin-based biomaterials together with halofuginone and methods of using thereof.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 28, 2017
    Assignee: KeraNetics, LLC
    Inventors: Seth Tomblyn, Luke Burnett, Scott Washburn
  • Patent number: 9821030
    Abstract: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: November 21, 2017
    Assignee: RegeneRx Biopharmaceuticals, Inc.
    Inventors: David Crockford, Allan L. Goldstein
  • Patent number: 9822149
    Abstract: The present disclosure relates to a polypeptide having multiple directionality and a self-assembled nanostructure containing the same. Since R1 and R3 domains having ?-sheet structures are arranged to have antiparallel structures, it provides a more stabilized ?-helix structure than the existing polypeptide having single directionality. In addition, since the polypeptide of the present disclosure is prepared as an antiparallel pseudo-cyclic structure without additional structural element such as a linker, the associated synthesis process is simple and the molecular weight is relatively small. Since the polypeptide having multiple directionality having the structural and functional characteristics described above and a self-assembled nanostructure containing the same have excellent stability and transportability, they are applicable in various fields as drugs, for detection of substances in vivo, for targeting for drug delivery, and for inhibiting protein-mediated biomacromolecular interactions.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: November 21, 2017
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Yong-Beom Lim, Woo-Jin Jeong
  • Patent number: 9808553
    Abstract: Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: November 7, 2017
    Assignee: HAEMOSTATIX LIMITED
    Inventors: Greg Walker, Sarah Margaret Middleton
  • Patent number: 9809621
    Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 7, 2017
    Assignee: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Patent number: 9795551
    Abstract: A tetrapeptide having antioxidant activity is provided. The tetrapeptide has a structure comprising, in amino acid sequence from N-terminus to C-terminus: tryptophan-X-tyrosine-X; wherein X is arginine, lysine, histidine or any positively-charged amino acid derivative such as 5-hydroxylysine, ornithine, 2,4-diamino-butyrate and 2,3-diamino-propionate. Each amino acid of the sequence or its Homo-amino acid derivative is independently of the D configuration (D-stereoisomer) or of the L configuration (L-stereoisomer), and the C-terminal comprises one selected from the group consisting of carboxyl (—COOH), and carboxamide (—CONH2). A composition stabilized to oxidation or having antioxidant activity and a method for attenuating effects of free radicals on a keratinous material are also provided.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: October 24, 2017
    Assignee: L'OREAL
    Inventors: Jean-Marc Sabatier, Zhi Pan
  • Patent number: 9777052
    Abstract: R-spondin variants comprising a ZNRF3 binding region of a first R-spondin and an LGR4 binding region of a second R-spondin are disclosed. Cell culture media and compositions containing the R-spondin variants, as well as methods of their use, are also disclosed.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: October 3, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Augen A. Pioszak
  • Patent number: 9770484
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: September 26, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Patent number: 9772334
    Abstract: Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: September 26, 2017
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Hon Wai Koon, Charalabos Pothoulakis, Avinoam Dukler
  • Patent number: 9770483
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: September 26, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Patent number: 9771395
    Abstract: Designed polypeptides having the amino acid sequence of SEQ ID NQ: 1 are described that bind with high affinity and selectivity to the influenza hemagglutinin protein, and which can be used for treating and/or limiting an influenza infection, as well as diagnosing an influenza infection and identifying candidate compounds for treating an influenza infection.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: September 26, 2017
    Assignee: University of Washington
    Inventors: Merika Treants Koday, Deborah L. Fuller, Aaron Chevalier, Jorgen Nelson, David Baker
  • Patent number: 9764040
    Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: September 19, 2017
    Assignee: Pfizer Inc.
    Inventors: Chakrapani Subramanyam, Frank Erich Koehn, Kenneth John Dirico, Alessandra S. Eustaquio, Michael Eric Green, Haiyin He, Min He, Christopher John O'Donnell, Sujiet Puthenveetil, Anokha Ratnayake, Jesse Alexander Teske, Hui Yu Yang
  • Patent number: 9763977
    Abstract: Embodiments of the invention provide bio-reactor circuits for in vitro research applications. One embodiment provides a bio-reactor circuit comprising at least one bio-reactor and a pump fluidically coupled to the at-least-one bio-reactor. The bio-reactor comprises a housing having inlet and outlet ports and first and second chambers. The chambers are separated by a porous membrane with the first chamber providing a flow path for a fluid. The membrane includes a coating having a cell binding affinity for the attachment and proliferation of cells to cover the surface of the membrane. The second chamber provides a volume for maintaining the viability of cells disposed in the chamber. The cells can be selected to produce a biochemical compound. The membrane is configured to allow for diffusion of the compound from the second chamber into the flow path as well as allow for diffusion of gases, nutrients and other biochemical compounds.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 19, 2017
    Assignee: INCUBE LABS, LLC
    Inventor: Mir Imran
  • Patent number: 9763936
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 19, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Ramiro Castro, Angelo Ceci
  • Patent number: 9757330
    Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: September 12, 2017
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Felice Cheng, Maggie J. M. Lu, Yi-Ju Ko, Min-Ying Lin, Shuen-Hsiang Chou
  • Patent number: 9758807
    Abstract: Fusion proteins comprising a protein expression enhancing polypeptide linked to a target protein binding domain and nucleic acid molecules encoding such fusion proteins are described for use in enhancing expression and/or location of a targeted protein of interest, for restoring lost functions in cells, and for treating disease. Additional fusion proteins comprising a target protein of interest modified with a fusion partner comprising a protein expression enhancing polypeptide are also disclosed.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: September 12, 2017
    Assignee: SOLA Biosciences, LLC
    Inventors: Akinori Hishiya, Keizo Koya, Luca Rastelli
  • Patent number: 9753018
    Abstract: The invention provides a method of improving an antioxidant effect in a redox pathway that involves selenium in a subject, an in vitro method of inhibiting oxidation in a cell or tissue, and an in vitro method of promoting proliferation of a cell, by use of a selenium-containing compound of chemical formula 1:
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 5, 2017
    Assignee: Fisheries Research Agency
    Inventors: Yumiko Yamashita, Michiaki Yamashita, Takeshi Yabu
  • Patent number: 9744213
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: August 29, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Patent number: 9744247
    Abstract: The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: August 29, 2017
    Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), FUNDACIÓ PARC CIENTÍFIC DE BARCELONA, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA), UNIVERSITAT DE BARCELONA, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA, UNIVERSITAT AUTÒNOMA DE BARCELONA
    Inventors: Leonor Ventosa Rull, Jaume Veciana Miró, Ingrid Cabrera Puig, Elisa Elizondo Saez De Vicuña, Marta Melgarejo Diaz, Miriam Royo Expósito, Fernando Albericio Palomera, Daniel Pulido Martinez, Santiago Sala Vergés, Jose Luis Corchero Nieto, Simón Schwartz Navarro, Ibane Abasolo Olaortua, Antonio Pedro Villaverde Corrales